Completed PHASE1 INTERVENTIONAL 6-arm NCT03586037

Evaluating the Pharmacokinetic Interaction Between AD-2011 and AD-2012

An Open-label, Sequence-randomized, Three-period, Six-sequence, Multiple Dosing Crossover Clinical Trial to Evaluate the Pharmacokinetic Interaction Between AD-2011 and AD-2012 in Healthy Male Volunteers

Sponsor: Addpharma Inc.

Conditions Hyperlipidemias Hypertension

Interventions AD-2011 10/20 mg AD-2011 10/20 mg + AD-2012 80mg AD-2012 80mg

Updated 6 times since 2018 Last updated: Oct 8, 2018 Started: Jun 12, 2018 Primary completion: Aug 9, 2018 Completion: Aug 20, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03586037, this PHASE1 trial focuses on Hyperlipidemias and Hypertension and remains completed. Sponsored by Addpharma Inc., it has been updated 6 times since 2018, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Nov 2018 — Jan 2021 [monthly]

Completed PHASE1

Status: Recruiting → Completed

▶ Show 1 earlier version

Aug 2018 — Nov 2018 [monthly]

Recruiting PHASE1

First recorded

Jun 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Addpharma Inc.

Data source: Addpharma Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea